Obimet GX 3 Tablet PR is a combination oral antihyperglycemic medication containing Glimepiride 3mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose utilization. The prolonged-release formulation ensures a steady plasma concentration, promoting sustained glycemic control and potentially reducing gastrointestinal side effects commonly associated with immediate-release metformin. Obimet GX 3 Tablet PR is prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels in patients inadequately controlled by monotherapy. It is essential to monitor blood glucose regularly to adjust dosage and prevent hypoglycemia. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to components. Caution is advised in patients with hepatic dysfunction, cardiovascular disease, or conditions predisposing to hypoxia. Common adverse effects include gastrointestinal disturbances and hypoglycemia. Patient education on adherence, lifestyle modification, and recognition of hypoglycemia symptoms is crucial for effective diabetes management with Obimet GX 3 Tablet PR.

Dosage & How to Use